CSL Ltd. — Investor Presentation 2023

Mar 27, 2023

For immediate release

28 March 2023

==> picture [595 x 197] intentionally omitted <==

CSL European Investor Site Tour Presentations

The presentation materials to be used for an Investor Site Tour being conducted by CSL (ASX:CSL; USOTC:CSLLY) in Europe this week are attached for the information of investors.

Authorised By

Fiona Mead

Company Secretary

For further information, please contact:

Investors:	Media:
Bernard Ronchi	Bernadette Murdoch
Investor Relations	Communications
CSL Limited	CSL Limited
P: +61 3 9389 3470	P: +61 449 950 745
E: bernard.ronchi@csl.com.au	E: Bernadette.murdoch@csl.com.au

Investor Tour, CSL Behring/Vifor European Operations March 2023

==> picture [960 x 80] intentionally omitted <==

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL ) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange ( ASX ), available at www.asx.com.au This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

Legal Notice

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL’s ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

2

CSL is expanding our capabilities by building an integrated, worldclass network of internal sites as well as contract manufacturers, with focus on Reliability, Quality, Cost, Innovation and Safety

Key CMO Partners Abbvie Fresenius Kabi Alphasigma Thermo Fisher Corden UniQure

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

3

CSL Behring Manufacturing Sites

==> picture [58 x 34] intentionally omitted <==

Bern, Switzerland (1,800+ employees)

Products: Immunoglobulins (IG), Albumin anti-D-hyperimmune, potential CSL112

==> picture [58 x 37] intentionally omitted <==

Broadmeadows, Australia (1,300+ employees)

Products: IG, Albumin, potential CSL112 and Coagulation factor toll manufacturing services for Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan

==> picture [59 x 34] intentionally omitted <==

Marburg, Germany (2,900+ employees)

Products: Albumin, IG & Albumin paste, Coagulation factors and Hyperimmunes

==> picture [438 x 143] intentionally omitted <==

==> picture [59 x 34] intentionally omitted <==

Kankakee, US (1,500+ employees)

Products: Albumin, IG intermediate paste, Coagulation factors, alpha1-proteinase inhibitor, PCC & C1 intermediates

==> picture [58 x 39] intentionally omitted <==

Wuhan, China (240+ employees)

Products: Albumin & Immunoglobulins for the Chinese market.

==> picture [59 x 35] intentionally omitted <==

Lengnau, Switzerland (Operated by Thermo Fisher) Products: Idelvion and other recombinant products Scheduled to begin manufacturing in FY24

4

Donor to Patient

==> picture [920 x 323] intentionally omitted <==

----- Start of picture text -----

Collection Testing Logistics Manufacturing
IMED Exchange Key Products
Fraction V Paste
Fractionation IV Paste (CSL 112) Privigen
Precipitate C Paste Alburex
I+II+III Paste / II+III Paste
Hizentra
Precipitate A
Indianapolis, IN Bern II+II+III Paste Bern …
I+III Paste
CSL Plasma Center Knoxville, TN Specialty Products
Rhophylac
Cryoprecipitate Human Albumin,
HAEGARDA, Beriplex,
DEAE Eluat; QAE-AS Precipitate
Cryoprecipitate; Albumin Paste Beriplast, AFSTYLA,
Dallas, TX
Marburg
Voncento Marburg Idelvion, …
Semi-finished
Kybernin
Goettingen, DE Water for injection vials Zemaira
Schwalmstadt, DE Alburex
Kankakee …
Kankakee
----- End of picture text -----

==> picture [960 x 139] intentionally omitted <==

----- Start of picture text -----

Fraction V Paste
Precipitate A Privigen
I+II+III Paste Alburex
WFI vials Toll
II/III Paste …
Broadmeadows Broadmeadows
| Confidential – Internal Use Only
Cryoprecipitate
5
----- End of picture text -----

CSL Behring Operating Model

Value Stream Value Stream Value Stream Value Stream Bulk and Base Frac Fill Finish Packaging recombinant Quality Engineering & Maintenance Site Logistics and support Planning

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

6

Tier Meeting Cascade & Reliability Room

We are driving transparency, action and accountability across the CSL Behring business unit through our tier escalation process. The regular Tier Meetings are focused on operational performance review and escalations with a strong focus on reliable supply to patients.

Tier Meetings ensure a daily cascade of critical issues within the site involving all operational functions. Supply "smoke signals" are elevated to the weekly Reliability Room ensure appropriate resolution and/or contingency planning.

==> picture [579 x 221] intentionally omitted <==

----- Start of picture text -----

Tier 4 Reliability
Room
weekly
Tier 3
Bern BMW Marburg Kankakee
daily
Tier 2
VS
VS Basefrac VS BULK VS FILL QC
Packaging
daily
Tier 1
Shop floor Shop floor Shop floor Shop floor Laboratories
daily
----- End of picture text -----

==> picture [183 x 287] intentionally omitted <==

----- Start of picture text -----

People
Safety
Quality
Reliability
Innovation
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

7

==> picture [199 x 42] intentionally omitted <==

Operational Highlights

==> picture [54 x 54] intentionally omitted <==

Manufacturing

• Broadmeadows and Marburg new base fractionation facilities licensed and operational

• Continued investment in short and long term yield/capacity initiatives:

• Albumin in Broadmeadows

• IgG in Bern

==> picture [54 x 54] intentionally omitted <==

Plasma Collections 1H23

• Strong increase in plasma collected +36% with levels now 10% above pre-pandemic

• Mexico border re-opened with collections recovering strongly

• • 7 new centers in US and 1 in Germany

• Continued adoption of technology

• CSL Plasma donor app – downloads >2.5m

• − Online health questionnaire

• RIKA program commenced

==> picture [256 x 454] intentionally omitted <==

==> picture [74 x 56] intentionally omitted <==

8

==> picture [145 x 145] intentionally omitted <==

==> picture [145 x 145] intentionally omitted <==

==> picture [145 x 145] intentionally omitted <==

==> picture [145 x 145] intentionally omitted <==

Network Asset Financial & Risk Capacity Management Resource Management Optimization

Our focus on Network Strategy ensures both a resilient and reliable Supply Chain

==> picture [74 x 56] intentionally omitted <==

9

Network Resiliency

Ensuring safe, reliable product supply for our patients across a complex, global supply chain.

Fractionation

Plasma

• Optimizing annual center expansions to align with IG demand & yield forecasts.

• Adding right-time capacity and balancing risk

• Optimizing supply chain.

• Balancing new builds vs. center efficiency vs. donor marketing & remuneration

Fill / Finish

Bulk

• Balancing CSL investment across sites and broadening knowledge of key products to across the network

• Leveraging relationships with key partners to find the right expertise, optimize production flexibility & ROIC

• Reducing Supply Chain Lead Times

• Timing new capacity to ensure supply & maximize ROIC

==> picture [271 x 474] intentionally omitted <==

==> picture [74 x 56] intentionally omitted <==

10

CSL has continued to execute against our growth strategy

==> picture [262 x 195] intentionally omitted <==

==> picture [261 x 195] intentionally omitted <==

==> picture [261 x 195] intentionally omitted <==

Marburg

Broadmeadows

Bern

Fractionation Capacity Fractionation Capacity

Immunoglobulin Capacity

Superb execution by the project teams enabled approval of Marburg and Broadmeadows fractionation projects via a CBE-30 in the U.S. and utilization of non-injectable plasma for qualification, delivering an approval faster than conventional timelines.

==> picture [74 x 56] intentionally omitted <==

11

Key CSL Behring Capital Projects CSL conducts annual Long-Term Demand & Capacity Forecasts to ensure optimal timing for CapEx projects

Fractionation

Technology

• Rika Device Rollout

• Marburg & Broadmeadows Production Ramp In Progress

• New Quality Management System (Veeva)

• CSL112 paste – Broadmeadows, AU

• Base Frac – planning

Bulk & Finish

Other

• Zemaira Fill – TFS, US

• Asset retirement & replacement

• Albumin Bulk & Fill – BMW, AU

• CSL112 Bulk & Fill – Bern, CH

• IG Bulk – planning

==> picture [271 x 474] intentionally omitted <==

----- Start of picture text -----

•
Optimizing Spend
•
Maximizing ROIC
•
Balancing Risk
•
Leveraging CMOs
•
Ensuring Growth
----- End of picture text -----

==> picture [74 x 56] intentionally omitted <==

12

==> picture [876 x 474] intentionally omitted <==

----- Start of picture text -----

Annual CapEx Investment
Network Strategy & Portfolio Management continue to
focus on optimization of CapEx spend
$Billion USD
•
1.40 Optimizing Spend
1.37
1.29
1.10 •
1.08
Maximizing ROIC
1.00
0.28
0.86 (25%)
•
Balancing Risk
0.57
0.41 0.82 •
Leveraging CMOs
(75%)
•
Ensuring Growth
FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23
(Forecast)
Actuals Compliance & Efficiency Grow
----- End of picture text -----*

==> picture [74 x 56] intentionally omitted <==

*CSL CapEx Investment, Excluding Vifor

13

Enterprise Wide Quality Framework

==> picture [208 x 299] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

• ➢ A standardized, and compliant Quality Management System (QMS) for all CSL Limited businesses

• ➢ Provides CSL standards across the CSL network aligned with regulatory requirements

• ➢ Provides consistency towards regulators and authorities visiting our locations globally

==> picture [220 x 348] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [243 x 419] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

Quality Facts and Figures FY22

• ➢ CSL was subject to 406 good manufacturing practice

• (GMP) regulatory agency inspections around the world with no impact to our licenses

• ➢ 28 inspections of our manufacturing facilities

• ➢ 378 inspections of CSL Plasma centers

• ➢ CSL performed 676 Quality Audits of our suppliers to assure continued consistent high-quality materials from our partners

• ➢ 15 Corporate GXP Internal Audits have been completed across the CSL Group since the commencement of the program 2 years ago

==> picture [139 x 77] intentionally omitted <==

==> picture [214 x 43] intentionally omitted <==

==> picture [107 x 49] intentionally omitted <==

==> picture [120 x 51] intentionally omitted <==

==> picture [163 x 51] intentionally omitted <==

==> picture [148 x 50] intentionally omitted <==

15

Quality Culture & Continuous Improvement

Investments in Quality:

State of the art automation in manufacturing & laboratories Equipment and facilities to meet new sterile product regulations Modernized training assets for our plasma centers

==> picture [104 x 10] intentionally omitted <==

==> picture [256 x 198] intentionally omitted <==

==> picture [307 x 155] intentionally omitted <==

==> picture [307 x 173] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

16

Our 2030 Strategy in 4 Words: Driving Sustainable, Profitable Growth

1. Focusing – in therapeutic areas where we excel

2. Innovating – across our organization

3. Delivering – reliable supplies of our products as efficiently as possible

4. Growing – our pipeline with sustainable, trusted R&D platforms, and

5. Transforming – our digital intellect and technologies

17

==> picture [140 x 89] intentionally omitted <==

Biopharma in the Heart of the Capital 2023

==> picture [960 x 90] intentionally omitted <==

2

| External Use

02

Welcome to Bern!

==> picture [109 x 9] intentionally omitted <==

==> picture [103 x 23] intentionally omitted <==

3

Our Pioneering on the Bern Site

==> picture [7 x 7] intentionally omitted <==

----- Start of picture text -----

4
----- End of picture text -----

==> picture [149 x 10] intentionally omitted <==

----- Start of picture text -----

| Confidential – Internal Use Only
----- End of picture text -----

Functions in Bern

Commercial Enabling E2E Operations R&D Operations Functions Fractionation Commercial Operations CSL Behring Biologics Finance Bulk Intercontinental Research Center I&T Filling & Visual (sitem-insel) HR Commercial Operations Inspection Legal Switzerland Plasma Product Packaging Communications Development Maintenance & Utilities Global Regulatory Engineering Affairs Environment, Health & Safety (EHS) Quality & Quality Controll

5

Our People

==> picture [51 x 51] intentionally omitted <==

Diverse Workforce

• 1800 employees:

• 39% women / 61% men

• 65 nationalities

• 8.7 years of average tenure

• 43 years of average age

==> picture [52 x 51] intentionally omitted <==

Talents & Culture

• Early career concept

• 40 apprentices, trainees and internships

• Gender equality

• Equal pay certification

==> picture [257 x 383] intentionally omitted <==

6

Bern Leading Sustainable Technology to Reduce Environmental Impact

==> picture [658 x 231] intentionally omitted <==

• Since 2016, we have savings of about 6,000 MWh of energy and about 1,000 tons of CO . This 2 corresponds to 9% energy and 11% CO 2 savings compared to 2015.

• We have been using electricity exclusively from hydropower for several years.

Project idea to bring CO2 down to net 0

7

04

Products Bern

==> picture [109 x 9] intentionally omitted <==

==> picture [103 x 23] intentionally omitted <==

8

Product Portfolio CSL Behring – Northern Hemisphere

Critical Care

Immunology

Albumin Solutions Polyvalent Immunoglobulins Human Albumin Behring[®] Privigen[®] Alburex[®] , AlbuRx[®] , Albumex[®, ] Hizentra[®] Albuminar[®] Carimune[® ] NF Inhibitors Sandoglobulin[®] Berinert[®] P, Haegarda[®] Intragam[®] Kybernin[®] P Evogam[®] Other Trauma Therapies Hyperimmunes Beriplex[®] P/N, Coaplex, Kcentra[®] Rhophylac[®] , Rhesogam RiaSTAP[®, ] Haemocomplettan[®] P CytoGam[®] Thrombotrol[®] Beriglobin[®] P Prothrombinex[®] Berirab[®] P Hepatitis B IG P Behring[®] Tetagam[®] P

Wound Healing

Coagulation

Plasma-derived factor II Human Thrombin a.s. Recombinant factor VIII Afstyla[®] Recombinant factor IX Idelvion[® ] Factor VIII:C/von Willebrand factor Haemate[®] P, Humate[®] P, Biostate[®] Plasma-derived factor VIII Beriate[®] P, Monoclate[®] P, Biostate[® ] Plasma-derived factors X Factor X P Behring[®]

Beriplast[®] P Combi-Set

Fibrogammin[®] , Corifact®, Cluvot[®] Fibrinogen a.s.

Pulmonology

Zemaira[®]

Respreeza[®]

Seqirus

Afluria[®] Flucelvax[®] Tetra

Green: products manufactured in Bern

9

Bern Products

Immunoglobulins

==> picture [142 x 113] intentionally omitted <==

==> picture [123 x 114] intentionally omitted <==

Privigen[®] Hizentra[®]

25/50/100/200/400mL 5/10/20/50mL

3 years by +2 to +25 ° C 30 months by +2 to +25 ° C

==> picture [142 x 117] intentionally omitted <==

Hizentra® PFS

5/10/20mL

30 months by +2 to +25 ° C

==> picture [145 x 117] intentionally omitted <==

Rhophylac[®]

2mL

3 years by +2 to +8 ° C

Albumin

==> picture [163 x 118] intentionally omitted <==

Alburex® 5%

100/250/500mL

Alburex® 20%

50/100mL

Alburex[®] 25%

CSL112

==> picture [71 x 71] intentionally omitted <==

Promotes

cholesterol removal leading to plaque stabilization

Reduction of recurrent heart attacks and stroke

50/100mL

3 years by +2 to +30 ° C

==> picture [31 x 32] intentionally omitted <==

Current Products

Serving patients and people in 100+ countries

Future Product

10

03

CSL Behring’s Presence & Innovation in Bern

==> picture [109 x 9] intentionally omitted <==

==> picture [103 x 23] intentionally omitted <==

11

Facilites Site Bern

==> picture [848 x 398] intentionally omitted <==

----- Start of picture text -----

Value Stream
Value Stream
Value Stream Bulk
Packaging
Fractionation Value Stream
Filling
Packaging (1 facility)
Fractionation (1 facility) Privigen / Hizentra (3 facilities) Filling (3 facilities)
Albumin (1 facility) Pasteurisation / Incubation
(1 facility with 5 past baths)
CSL112 (1 facility)
Visual Inspection (2 facilities)
Rhophylac (1 facility)
----- End of picture text -----

12

Investments

==> picture [842 x 386] intentionally omitted <==

----- Start of picture text -----

180
160
140
120
100
80
60
40
20
0
2000/01 2001/02 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17 2017/18 2018/19 2019/20 2020/21 2021/22
----- End of picture text -----

13

Efficiency & Innovation

==> picture [270 x 214] intentionally omitted <==

==> picture [268 x 172] intentionally omitted <==

==> picture [296 x 286] intentionally omitted <==

----- Start of picture text -----

Growth IgG
More
batches
Increase
batch size
Increase
yield
----- End of picture text -----

IG Capacity

• Project delivered, ahead of schedule, on budget

• IgLAB Module V & VI IG capacity:

• Max capacity utilization demonstrated (14 batches per week)

Bulk & Filling Capacity

• Upgrade existing Phase 3 CSL112 bulk facility and install new filling line and lyophilises

• Minimize capital investment at risk

• Bern’s yearly production will supply approx. 80’000 patients per year

Automation

• Our new manufacturing site for visual inspection, secondary packaging and storage of intermediate and finished products

• Transition into fully automated final manufacturing from incubation to delivery

14

CSL R&D in Switzerland

==> picture [648 x 392] intentionally omitted <==

----- Start of picture text -----

Plasma Product Development Global Regulatory Affairs
GPS, CMC, BioProcess Sciences, BioAnalytical GRA CMC, GRA OpX, GRA GPS, GRA
Science, Breakthrough Launchpad, Primary Policy & Intelligence
Packaging & Medical Devices
Wankdorfstrasse
27%
Feusi
45%
Sitem-Insel
20%
8%
Research
Other R&D functions Biochemistry, Gene Therapy
Project Management, Research, Preclinical Innovation,
Pharmacology & Translational Translational Research, Research
Development, Clinical Safety, External Innovation
Global Licensing, IP
----- End of picture text -----

==> picture [430 x 339] intentionally omitted <==

----- Start of picture text -----

Global Regulatory Affairs
300+ (500+)
GRA CMC, GRA OpX, GRA GPS, GRA
Policy & Intelligence R&D employees
3 (6)
sites
17 225
collaborations with scientific papers
academic institutions published with our
and hospitals in EU collaborators since
and CH 2015
32
nationalities
Biochemistry, Gene Therapy
Research, Preclinical Innovation,
Translational Research, Research 56
External Innovation languages
----- End of picture text -----

15

R&D Cooperations

==> picture [960 x 339] intentionally omitted <==

16

Memberships & Community Commitments

==> picture [149 x 47] intentionally omitted <==

==> picture [143 x 49] intentionally omitted <==

==> picture [208 x 41] intentionally omitted <==

==> picture [326 x 47] intentionally omitted <==

==> picture [165 x 30] intentionally omitted <==

==> picture [60 x 54] intentionally omitted <==

==> picture [127 x 76] intentionally omitted <==

==> picture [180 x 82] intentionally omitted <==

==> picture [221 x 30] intentionally omitted <==

==> picture [227 x 97] intentionally omitted <==

==> picture [144 x 45] intentionally omitted <==

==> picture [97 x 68] intentionally omitted <==

==> picture [97 x 97] intentionally omitted <==

17

05

Thank you for your attention!

==> picture [109 x 9] intentionally omitted <==

==> picture [103 x 23] intentionally omitted <==

18

Welcome to Marburg Investor Tour 28 March 2023

Michael Schröder, Site Head Marburg The picture shows Kathrin Schön, one of our HAE patients

CSL Behring Marburg Operations Site Overview

Focus on Reliable Supply

==> picture [677 x 381] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

3

Marburg at a Glance

==> picture [662 x 374] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

4

Behringwerke Campus Main Plant

H69 Filling/Packaging H68 Base Fractionation/ Bulk Plasma H67 Recombinant BDI

==> picture [67 x 50] intentionally omitted <==

5

Behringwerke Campus Görzhausen

==> picture [243 x 209] intentionally omitted <==

M483/M486/M484 Warehouses (operated by Pharmaserv) M305 Filling/Bulk Plasma M300 Bulk Plasma & Recombinants M240 QC Labs/Support M245 New Base Fractionation

==> picture [67 x 50] intentionally omitted <==

6

Our Technical Capabilities

==> picture [860 x 93] intentionally omitted <==

Plasma

Recombinant Flu

==> picture [67 x 50] intentionally omitted <==

7

Focus on Inframarginals

==> picture [404 x 319] intentionally omitted <==

----- Start of picture text -----

Beriate ®
Plasma
Humate ® P
Haemate ® P
RiaSTAP ®
Haemocomplettan ®P
Cryodepleted plasma
Beriplast ®
Beriplex ® Kcentra
Berinert ® HEAGARDA ®
8 % Precipitation
(Fraction I)
Fibrogammin ®
factor XIII
Beriplast ®
Kybernin ®
Corifact ®
25% Precipitation
(Fraction II + III)
Immunoglobuline (incl.
hyperimmunes)
40% Precipitation
(Fraction V)
Albumin
----- End of picture text -----

==> picture [391 x 356] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

8

Product Portfolio of CSL Behring – Northern Hemisphere

Albumin solutions Human Albumin Behring® Alburex ®, AlbuRx®, Albumex ®, Albuminar ® Inhibitors Berinert® P, Haegarda®,Berinert SC® Kybernin® P Other trauma therapies Beriplex® P/N, Coaplex, Kcentra® RiaSTAP ® Haemocomplettan® P Thrombotrol® Prothrombinex® Critical Care Wound Healing	Polyvalent immunoglobulins Privigen® Hizentra® Carimune®NF Sandoglobulin® Intragam® Evogam ® Hyperimmunes Rhophylac® ,Rhesogam CytoGam® Beriglobin® P Berirab® P Hepatitis B IG P Behring® Tetagam® P Immunology	Coagulation
		Plasma-derived factor II Human Thrombin active substance Recombinant factor VIII Afstyla® Recombinant factor IX Idelvion® Factor VIII:C/von Willebrand factor Haemate® P, Humate® P,Biostate® Plasma-derived factor VIII Beriate® P,Biostate® Plasma-derived factors X Factor X P Behring® Gene therapy Hemgenix®

Wound Healing

Beriplast[® ] P Combi-Set Fibrogammin[®] , Corifact[®, ] Cluvot[®] Fibrinogen active substance

Pulmonology Zemaira[®] Respreeza[®]

Seqirus Afluria[®] Flucelvax[®] Tetra

Green: products manufactured in Marburg Red: products filled and/or finished in Marburg

9

Take a look inside our manufacturing

==> picture [292 x 237] intentionally omitted <==

==> picture [149 x 10] intentionally omitted <==

----- Start of picture text -----

| Confidential – Internal Use Only
----- End of picture text -----

==> picture [10 x 7] intentionally omitted <==

----- Start of picture text -----

10
----- End of picture text -----

==> picture [315 x 167] intentionally omitted <==

==> picture [252 x 167] intentionally omitted <==

==> picture [373 x 250] intentionally omitted <==

Focus on our People

• Lean and agile culture and working environment

• Embedded in the community

• Well-established relations with universities

• Focus on future talent

==> picture [257 x 383] intentionally omitted <==

11

Add Green to CSL's Red

"Phoenix" – New Base Fractionation Facility

M600 – R&D Cube

• Investment: USD ~ 170M

• Investment: USD 470M

• Highest energy standards (ice storage combined with heat pump)

• Sustainable and energyefficient planning

• Highest KfW-credit in history (EUR 250M)

• 500 R&D employees under one roof

• Fractionation capacity increased by 4

==> picture [257 x 454] intentionally omitted <==

==> picture [134 x 98] intentionally omitted <==

Marburg's St. Elizabeth's Church lights up for "Rare Disease Day" 28 February 2023

Elena is impacted by iron deficiency

Maximizing the Iron Opportunity CSL Vifor

Hervé Gisserot General Manager CSL Vifor

Our Future is Built on the Framework of Our Rich Iron Heritage

==> picture [848 x 323] intentionally omitted <==

----- Start of picture text -----

Ferinject/Injectafer
Vifor Fresenius achieves block-
Medical Care Renal buster status
Pharma (VFMCRP) 2019
established
Galenica acquires
2010
Vifor Ltd.
Foundation for
1977
Galenica Ltd. formed
1927
2022
CSL Limited
2017
acquires
Vifor Pharma becomes Vifor Pharma
2007
independent, stock-
Ferinject receives listed company
1944 first regulatory
approvals
Vifor Ltd.
1872
established,
Pharmacy founded by marketing hospital
Caspar Friedrich Haus- supply products
mann in St. Gallen,
Switzerland pioneering
iron products
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

2

We are a Global Leader in Iron Replacement and Nephrology Therapies

Iron Replacement Further expansion in anemia; growth through HF, PBM and geographic expansion

Nephrology

Launching the next generation of therapies addressing kidney disease progression

Dialysis

Non-Dialysis

In Market

Pipeline

==> picture [80 x 29] intentionally omitted <==

==> picture [84 x 33] intentionally omitted <==

==> picture [110 x 24] intentionally omitted <==

Heart failure opportunity & geographic expansion

==> picture [489 x 121] intentionally omitted <==

----- Start of picture text -----

1
4
2
5
3
(Ex-US)
SNF-472 Sparsentan [7]
vadadustat [6] INS-3001 vamifeport
----- End of picture text -----

Note: HF = heart failure. PBM = patient blood management. | 1 Licensed from F. Hoffman-La Roche AG. | 2 Licensed from Pfizer Inc. | 3 Licensed from ChemoCentryx, Inc. | 4 Licensed from OPKO Health, Inc. | 5 Licensed from Cara Therapeutics, Inc. | 6 Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to selling Vadadustat to certain providers within the US dialysis market. Status pending - Complete Response Letter received from FDA due to safety concerns. | 7 Licensed from Travere Therapeutics, Inc.

==> picture [109 x 10] intentionally omitted <==

3

Iron Replacement: CSL Vifor’s Largest Franchise 1H23 revenue by therapy group1 In $m	Iron Replacement: CSL Vifor’s Largest Franchise 1H23 revenue by therapy group1 In $m
Therapy Group Sales1	$m 48%, Iron, $427 42%, Dialysis, $377 6%, Non Dialysis, $55 4%, Other, $30
Ferinject/Injectafer Iron 315
Mircera Dialysis 258
Velphoro Dialysis 77
Venofer Iron 74
Veltassa Non Dialysis 49
Maltofer Iron 36

1 ~5 months revenue contribution ( Acquired 9th August 2022)

==> picture [109 x 10] intentionally omitted <==

4

==> picture [350 x 229] intentionally omitted <==

The number of ID[1] patients without IDA[2] is estimated to be more than twice as many as the number of IDA patients[3,4]

What is Iron Deficiency? Significant global prevalence

Iron ID Anaemia Deficiency ~1.2B people[5] >3B people

1. ID = Iron Deficiency; 2. IDA = Iron Deficiency Anaemia, occurs when ID is sufficiently severe to reduce erythropoiesis; 3. Iron deficiency (Blood. 2019;133(1):30 – 39) – Anaemia still affected one third of the population, with approximately half of the cases resulting from iron deficiency. The estimate is that 1.24 billion individuals experience iron deficiency anaemia. The global prevalence of iron deficiency without anaemia remains elusive, although the suggested figure is at least double that of iron deficiency anaemia; 4. These numbers are estimates, most studies either have a geographical focus or are done in specific subpopulations. 5. Blood. 2014 Jan 30;123(5):615-24.

==> picture [109 x 10] intentionally omitted <==

5

==> picture [352 x 229] intentionally omitted <==

A market Leader in High Dose IV Iron Segment[1]

• 1.2B CHF in-market sales in 2022

• 28% market share of overall Iron market (Global In-Market Sales (MAT Q4 2022)

• 47% market share in IV iron segment

• More than 22 million patient years of exposure

Significant untapped potential with Ferinject[®] /Injectafer[®]

==> picture [467 x 310] intentionally omitted <==

----- Start of picture text -----

Majority of patients yet to be
diagnosed & treated (EU5 only)
-89%
-59%
-21%
5.3M -50%
-33%
2.2M
1.8M
0.9M
0.6M
Patients with ID/IDA Diagnosed ID/IDA Treated for ID/IDA Treated with IV Iron Treated with
Ferinject®
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

1. IQVIA MIDAS Quarterly panel, GERS, Insight Health, DN, DLI.; Average 2022 exchange rates have been applied. ID = Iron Deficiency. IDA = Iron Deficiency Anaemia. 6

Priorities to accelerate Ferinject[®] /Injectafer[®] growth

Areas of focus

Strategic priorities

Focused targeting, amongst the many different patients suffering from ID and IDA

==> picture [83 x 86] intentionally omitted <==

==> picture [72 x 76] intentionally omitted <==

==> picture [51 x 74] intentionally omitted <==

Heart Chronic Kidney Patient Blood Failure (HF) Disease Management (PBM)

Maximise penetration ex-US

• Explore potential revenue synergies with CSL Behring on PBM

• Geographic expansion

Maximise penetration in the US

• Improve access

• Successfully launch HF indication with our partner American Regent (Daiichi Sankyo)

Explore other avenues for product differentiation

==> picture [109 x 10] intentionally omitted <==

ID = Iron Deficiency. IDA = Iron Deficiency Anaemia.

7

==> picture [960 x 430] intentionally omitted <==

29 March 2023

CSL Vifor St. Gallen, Home of Iron

Hans-Martin Müller Head Manufacturing Iron & Strategic Projects

Employees are our most valuable asset, empowered to creating their own career journey with us

Head Count

Share of FTE’s

Time with CSL Vifor

==> picture [860 x 313] intentionally omitted <==

----- Start of picture text -----

30%
26%
23%
25%
20%
16%
15%
10% 11%
7%
10%
7%
5%
0%
< 1 year 1-2 years 3-5 years 6-10 years 11-15 years 16-20 20+ years
years
33% 62% 27 10
Share of women Share of educational Different nations Apprentices
•
10% Director + attainment at "tertiary
•
37% Manager level" (Universities & higher
vocational training)
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

9

CSL Vifor’s rich heritage dates back to 1872 when the success story of iron began in St. Gallen

==> picture [838 x 315] intentionally omitted <==

----- Start of picture text -----

Construction of new
Vifor joins CSL
building and plant
(August 2022)
for iron chloride
manufacturing 2022
2020
First Approval
First Approval 2013
1964
First Approval
1949
2023
Capacity Increase
2021
Ferinject/Maltofer
2018 Latest Capacity “Multicube building”
Increase Velphoro
2007 Latest Capacity
Increase Venofer
First Approval
1952
1872 Moving into the Site at
Rechenstrasse
Everything began in in St. Gallen
St. Gallen/Formation of
Hecht Pharmacy by
Caspar Friedrich
Hausmann
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

10 Confidential – Internal Use Only

All iron products were discovered, developed and are produced in St. Gallen to this date

==> picture [423 x 287] intentionally omitted <==

==> picture [231 x 132] intentionally omitted <==

==> picture [193 x 287] intentionally omitted <==

==> picture [231 x 156] intentionally omitted <==

11

The manufacturing site in St. Gallen focuses mostly on API production of its iron products

==> picture [645 x 172] intentionally omitted <==

==> picture [646 x 181] intentionally omitted <==

API manufacturing in St.Gallen

FP Contract Manufacturing

==> picture [109 x 10] intentionally omitted <==

12

Complex manufacturing turns iron ore into the active pharmaceutical ingredients (API) of our iron therapies

==> picture [846 x 97] intentionally omitted <==

----- Start of picture text -----

Iron Ore FeCl3 Synthesis Drying Finished Products
Iron – from Iron Precursor Manufacturing by
API Synthesis
Mine to SG Synthesis CDMO's
----- End of picture text -----

==> picture [415 x 204] intentionally omitted <==

==> picture [109 x 10] intentionally omitted <==

13

Over 1,000 tons of iron based API’s are produced in St. Gallen per year

==> picture [426 x 335] intentionally omitted <==

----- Start of picture text -----

Produced quantity of API
(tons of API)
1200
+ 58%
1000
800
600
400
200
0
2016 2017 2018 2019 2020 2021 2022
----- End of picture text -----

FDA-Inspection History

2000	PAI Venofer
2007	GMP Conformity Without deficiencies
2010	GMP Conformity Without deficiencies
2012	PAI Velphoro Without deficiencies
2016	GMP Conformity Without deficiencies
2021	GMP Conformity, (Mail Audit) Without deficiencies

==> picture [109 x 10] intentionally omitted <==

14

Best Use of nearby sustainable Energy Sources

Participation in two River Power Plants since 2018

Future use of Communal District Heating

==> picture [398 x 189] intentionally omitted <==

==> picture [189 x 73] intentionally omitted <==

==> picture [203 x 73] intentionally omitted <==

Aim: Reduction of CO 2 Footprint by >80%

==> picture [109 x 10] intentionally omitted <==

15

Learn more about our iron expertise on today’s tour through the St. Gallen site

==> picture [521 x 343] intentionally omitted <==

----- Start of picture text -----

5
8
4
3
2
1
----- End of picture text -----

1 The iron exhibition

2 From rock to iron dust 3 Take iron seriously 4 Nanomedicines 5 In the heart of the factory 6 The success story continues

==> picture [109 x 10] intentionally omitted <==

16

Behavioral Rules for the Tour

Do not take photos on the site.

Wear the specified personal protective equipment correctly during the tour. Do not touch any pipes, apparatus or surfaces.

==> picture [249 x 173] intentionally omitted <==

==> picture [298 x 344] intentionally omitted <==

==> picture [249 x 172] intentionally omitted <==

==> picture [109 x 10] intentionally omitted <==

17

Our local experts will guide you through the iron experience today

==> picture [327 x 152] intentionally omitted <==

----- Start of picture text -----

Group “Green” Group “Blue”
----- End of picture text -----

==> picture [501 x 152] intentionally omitted <==

----- Start of picture text -----

Group “Yellow” Group “Red” Group “Purple”
----- End of picture text -----

Hans-Martin Müller

Manuel Senn

Dominic Lampert

Markus Sonderegger

Philipp Bachmann

Head Manufacturing Iron & strategic projects

• With CSL Vifor for 23 years

• PhD in Organic Chemistry from the Federal Institute of Technology (ETH) Zurich, Switzerland

Site Head

• With CSL Vifor for 15 years

• Holds an BsC in Chemistry, focus on biochemistry, from the University of applied science in Winterthur, Switzerland

Head of Production

• With CSL Vifor for 13 years

• Holds a diploma in Industrial Engineering and Management from

• University of Mittweida, Germany

Head Quality Operations API, Manufacturing

Global Head Quality Management, TechOps

• With CSL Vifor for 12 • With CSL Vifor for 23 years years

• holds a Master in Biological Science from the University of Innsbruck, Austria

• holds a Master in Biochemistry from the Swiss Federal Institute of Technology in Zürich (ETH)

==> picture [109 x 10] intentionally omitted <==

18